Inovelon® (rufinamide) Drinkable Suspension Launches in Denmark (y 2)

1. Kenou van Rijckevorsel Treatment of Lennox-Gastaut syndrome: overview and recent findings. Neuropsychiatr Dis Treat. 2008 December; 4(6): 1001-1019.

2. MedScape references Lennox-Gastaut Syndrome http://emedicine.medscape.com/article/1176735-overview (Accessed February 2012)

3. Inovelon tablets Summary of Product Characteristics http://www.medicines.org.uk/emc/medicine... (Accessed January 2012)

4. International Journal of Pharma and Bio Sciences. http://www.ijpbs.net/issue-3/82.pdf (Accessed February 2012)

5. Pugliatti M et al. Estimating the cost of epilepsy in Europe: A review with economic modeling. Epilepsia 2007: 48(12) 2224-2233

6. ILAE/IBE/WHO,Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe 2010. Available from; http://www.ilae-epilepsy.org/Visitors/Documents/EUROReport16... (Accessed February 2011)

7. Epilepsy Society UK: http://www.epilepsysociety.org.uk/AboutE... (Accessed February 2012)

8. Forsgren L. Epilepsy in Children.2nd Ed London.Arnold, 2004. 21-25

9. Epilepsy Research UK. What is Epilepsy? Fact sheet. Available from URL: http://www.epilepsyresearch.org.uk/about... (Accessed February 2012)

CONTACT: Media Enquiries, Eisai Europe Ltd, Charlotte Andrews / CressidaRobson, +44-(0)7947-231513 / +44-(0)-790-831-4155,charlotte_andrews@eisai.net / cressida_robson@eisai.net ; Tonic LifeCommunications, Benjamyn Tan / Leah Peyton, +44-(0)-207-798-9262 /+44-(0)-7788-191434, benjamyn.tan@toniclc.com / leah.peyton@toniclc.com